Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
acetomenaphthone
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Small Molecules
- Administration
- Oral, Intravenous, Intramuscular
01
Overview
Vitamin K4 (acetomenaphthone) is a synthetic, water-soluble analog of vitamin K. It serves as a precursor to active vitamin K forms (such as vitamin K2) in the body, acting as an essential cofactor for gamma-glutamyl carboxylase (GGCX) to promote the post-translational carboxylation of clotting factors (factors II, VII, IX, and X) and anticoagulant proteins (proteins C and S). Clinically, it is approved for the treatment and prevention of hypoprothrombinemia and hemorrhage associated with vitamin K deficiency or malabsorption. Beyond its role in coagulation, acetomenaphthone has been investigated for its anti-inflammatory properties via the inhibition of the NLRP3 inflammasome, and its potential antineoplastic activity in various cancers, including prostate cancer, leukemia, and osteosarcoma. Recent preclinical research also highlights its potential in attenuating renal ischemia-reperfusion injury.
- Brand names
- AdaprinDavitamon-KKapathromKapilinKapilonKappaxanKayvitePafavitProkayvit OralSynkayvite
- Other names
- 1,4-diacetoxy-2-methylnaphthalene2-methyl-1,4-naphthalenediol diacetate2-methyl-1,4-naphthylene diacetate2-methylnaphthalene-1,4-diyl diacetateacetomenadioneacetomenaphtoneacetomenaphthonemenadiol diacetatevitamin K diacetatevitamin K4
02
Targets
GGCX (Vitamin K-dependent gamma-glutamyl carboxylase)NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)
Beyond the preview
Go deeper on acetomenaphthone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on acetomenaphthone.